BRPI0514314A - method for detecting and discriminating between colorectal adenoma and / or colorectal carcinoma, method for monitoring development and / or course and / or treatment of colorectal adenoma and / or colorectal carcinoma, use of c3a or derivative thereof, test system, kit comprising molecules, method for determining whether a compound is effective in the treatment of colorectal adenoma and / or colorectal carcinoma - Google Patents

method for detecting and discriminating between colorectal adenoma and / or colorectal carcinoma, method for monitoring development and / or course and / or treatment of colorectal adenoma and / or colorectal carcinoma, use of c3a or derivative thereof, test system, kit comprising molecules, method for determining whether a compound is effective in the treatment of colorectal adenoma and / or colorectal carcinoma

Info

Publication number
BRPI0514314A
BRPI0514314A BRPI0514314-4A BRPI0514314A BRPI0514314A BR PI0514314 A BRPI0514314 A BR PI0514314A BR PI0514314 A BRPI0514314 A BR PI0514314A BR PI0514314 A BRPI0514314 A BR PI0514314A
Authority
BR
Brazil
Prior art keywords
colorectal
adenoma
carcinoma
treatment
colorectal carcinoma
Prior art date
Application number
BRPI0514314-4A
Other languages
Portuguese (pt)
Inventor
Hartmut Juhl
Kerstin David
Anne-Kristin Fentz
Original Assignee
Indivumed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2004/009124 external-priority patent/WO2006015616A1/en
Application filed by Indivumed Gmbh filed Critical Indivumed Gmbh
Publication of BRPI0514314A publication Critical patent/BRPI0514314A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

MéTODO PARA DETECçãO DE E DISCRIMINAçãO ENTRE ADENOMA COLORRETAL E/OU CARCINOMA COLORRETAL, MéTODO PARA MONITORAMENTO DE DESENVOLVIMENTO E/OU CURSO E/OU DE TRATAMENTO DE ADENOMA COLORRETAL E/OU CARCINOMA COLORRETAL, USO DE C3A OU DERIVADO DO MESMO, SISTEMA DE TESTE, CONJUNTO COMPREENDENDO MOLéCULAS, MéTODO PARA DETERMINAR SE UM COMPOSTO EFETIVO NO TRATAMENTO DO ADENOMA. COLORRETAL E/OU CARCINOMA COLORRETAL A presente invenção tem como objetivo um método de detecção do adenoma colorretal e/ou carcinoma colorretal compreendendo os seguintes passos: a) fornecimento de uma amostra isolada de material a qual foi retirada de um indivíduo, b) determinação do nível de C3a ou seu derivado na dita amostra isolada de material, c) comparação do nível determinado de C3a ou seu derivado com um ou mais valores de referência. A invenção tem como objetivo ser um método para discriminação entre adenoma colorretal e carcinoma colorretal, assim como um método para monitoramento do curso do adenoma colorretal e/ou carcinoma colorretal e/ou tratamento do adenoma colorretal e/ou carcinoma colorretal. Além disso, a invenção tem como objetivo ser um sistema de teste e um conjunto para uso nesses métodos. Ademais, a invenção tem como objetivo o uso de C3a como biomarcador para a detecção do adenoma colorretal e/ou carcinoma colorretal em um indivíduo. Ainda, a invenção tem como objetivo ser um método para determinar se um composto é efetivo no tratamento do adenoma colorretal e/ou carcinoma colorretal.METHOD FOR DETECTION AND DISCRIMINATION BETWEEN COLORRETAL ADENOMA AND / OR COLORRETAL CARCINOMA, METHOD FOR MONITORING DEVELOPMENT AND / OR COURSE AND / OR TREATMENT OF COLORRETAL ADMINISTRATION, OR CUSTOMER SYSTEM, SET UNDERSTANDING MOLECULES, METHOD FOR DETERMINING IF AN EFFECTIVE COMPOUND IN TREATMENT OF THE ADENOMA. COLORRETAL AND / OR COLORRETAL CARCINOMA The present invention is directed to a method for detecting colorectal adenoma and / or colorectal carcinoma comprising the following steps: a) providing an isolated sample of material which has been taken from an individual, b) determining the level of C3a or its derivative in said isolated sample of material, c) comparing the determined level of C3a or its derivative with one or more reference values. The invention aims to be a method for discriminating between colorectal adenoma and colorectal carcinoma, as well as a method for monitoring the course of colorectal adenoma and / or colorectal carcinoma and / or treatment of colorectal adenoma and / or colorectal carcinoma. Furthermore, the invention aims to be a test system and assembly for use in these methods. Furthermore, the invention aims to use C3a as a biomarker for detecting colorectal adenoma and / or colorectal carcinoma in an individual. Further, the invention aims to be a method for determining whether a compound is effective in treating colorectal adenoma and / or colorectal carcinoma.

BRPI0514314-4A 2004-08-13 2005-08-11 method for detecting and discriminating between colorectal adenoma and / or colorectal carcinoma, method for monitoring development and / or course and / or treatment of colorectal adenoma and / or colorectal carcinoma, use of c3a or derivative thereof, test system, kit comprising molecules, method for determining whether a compound is effective in the treatment of colorectal adenoma and / or colorectal carcinoma BRPI0514314A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2004/009124 WO2006015616A1 (en) 2004-08-13 2004-08-13 Use of transthyretin as a biomarker for colorectal adenoma and/or carcinoma; method for detection and test system
PCT/EP2005/008742 WO2006053592A1 (en) 2004-08-13 2005-08-11 Use of c3a and derivatives thereof as a biomarker for colorectal ademona and/or carcinoma; diagnosis method and test system using the same

Publications (1)

Publication Number Publication Date
BRPI0514314A true BRPI0514314A (en) 2008-06-10

Family

ID=39473636

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514314-4A BRPI0514314A (en) 2004-08-13 2005-08-11 method for detecting and discriminating between colorectal adenoma and / or colorectal carcinoma, method for monitoring development and / or course and / or treatment of colorectal adenoma and / or colorectal carcinoma, use of c3a or derivative thereof, test system, kit comprising molecules, method for determining whether a compound is effective in the treatment of colorectal adenoma and / or colorectal carcinoma

Country Status (1)

Country Link
BR (1) BRPI0514314A (en)

Similar Documents

Publication Publication Date Title
BRPI0419002A (en) method for detecting and differentiating between colorectal adenoma and / or colorectal carcinoma, method for monitoring the course of colorectal adenoma, use of transthyretin as a biomarker, testing system, arrangement comprising detection molecules
PH12020551371A1 (en) Assays to detect neurodegeneration
NZ593514A (en) p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer
BR112014006741A2 (en) method for monitoring, diagnosis and / or prognosis of early acute kidney injury
BR112013000869A2 (en) method for diagnosing prostate cancer (pca) with a desired sensitivity in a subject; method for monitoring the progression of prostate cancer (pca) in a subject; method for assessing whether a subject has to undergo a prostate biopsy; kit comprising a first component and optionally a second component and use of a kit
MX357119B (en) Plasma micrornas for the detection of early colorectal cancer.
Exner et al. Testing for new oral anticoagulants with LA-resistant Russells viper venom reagents. An in vitro study
MY193564A (en) Detection reagent, detection kit and detection method for itga4 gene methylation
Brentnall et al. Proteins that underlie neoplastic progression of ulcerative colitis
Smith et al. Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma
KR101516086B1 (en) Method for diagnosing rheumatoid arthritis by using metabolomics
Tsilioni et al. Sestrin-2 is significantly increased in malignant pleural effusions due to lung cancer and is potentially secreted by pleural mesothelial cells
JP2014530350A5 (en)
BRPI0607350A2 (en) method for detecting the presence or quantity of an erroneously duplicated protein in a sample and kit
EP2585832A4 (en) REDUCTION OF FALSE RESULTS IN DOSAGE MEASUREMENTS
IL189185A0 (en) Use of an endoplasmin fragment and derivatives thereof as a biomarker for colorectal adenoma and/or carcinoma; method for detection and test system
BRPI0514314A (en) method for detecting and discriminating between colorectal adenoma and / or colorectal carcinoma, method for monitoring development and / or course and / or treatment of colorectal adenoma and / or colorectal carcinoma, use of c3a or derivative thereof, test system, kit comprising molecules, method for determining whether a compound is effective in the treatment of colorectal adenoma and / or colorectal carcinoma
CN105548546A (en) A lung cancer screening kit
Bonassi et al. 3-(2-deoxy-β-d-erythro-pentafuranosyl) pyrimido [1, 2-α] purin-10 (3H)-one deoxyguanosine adducts of workers exposed to asbestos fibers
ATE426168T1 (en) USE OF ASC AS A MARKER FOR COLORECTAL CARCINOMA
WO2007060240A3 (en) Method for demonstrating presence or absence of markers (eef1a1 or mark3 )associated with the presence and/or the chemosensitivity of tumors
ITTO20120523A1 (en) PROCEDURE AND KIT FOR IN VITRO DIAGNOSIS OF THE PANCREATIC ADOCOCARCINOMA DUCTAL OR TO DETERMINE THE PREPARATION FOR THE PANCREATIC DUCTAL ADENOCARCINOMA
TW200942819A (en) Alzheimer's disease-specific alterations of the ErK1/ErK2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (ADSMB)
Pang Effect of miR-21 on Oral Squamous Cell Carcinoma Cell Proliferation and Apoptosis Via Akt/PKB Signaling Pathway
ZHANG et al. Expression of LUNX and CK19 in non-small cell lung cancer and its significance

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 7A ANUIDADE.